CERO THERAPEUTICS HOLDINGS, INC.: 10-Q filed 2025-05-15
What CERO THERAPEUTICS HOLDINGS, INC. reported in its quarterly report filed 2025-05-15 (fiscal Q1 2025): 28 published measures, 67 facts as tagged in accession 0001213900-25-044335.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2025-05-15
- Fiscal period
- fiscal Q1 2025
- Accession
- 0001213900-25-044335 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CERO THERAPEUTICS HOLDINGS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 7,991,414 | USD | |
| At 2024-12-31 | 6,206,929 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 8,320,800 | USD | |
| At 2024-12-31 | 8,101,492 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | -329,386 | USD | |
| At 2024-12-31 | -1,894,563 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 5,100,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | -5,105,931 | USD | 90 |
| 2024-02-14 to 2024-03-31 | -1,727,483 | USD | 47 |
| 2024-01-01 to 2024-02-13 | -572,211 | USD | 44 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | -76,023,784 | USD | |
| At 2024-12-31 | -70,917,853 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 3,427,616 | shares | 90 |
| 2024-02-14 to 2024-03-31 | 141,125 | shares | 47 |
| 2024-01-01 to 2024-02-13 | 5,845 | shares | 44 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 3,427,616 | shares | 90 |
| 2024-02-14 to 2024-03-31 | 141,125 | shares | 47 |
| 2024-01-01 to 2024-02-13 | 5,845 | shares | 44 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | -1.59 | USD/shares | 90 |
| 2024-02-14 to 2024-03-31 | -12.24 | USD/shares | 47 |
| 2024-01-01 to 2024-02-13 | -97.9 | USD/shares | 44 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | -1.59 | USD/shares | 90 |
| 2024-02-14 to 2024-03-31 | -12.24 | USD/shares | 47 |
| 2024-01-01 to 2024-02-13 | -97.9 | USD/shares | 44 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 452,227 | USD | |
| At 2024-12-31 | 528,521 | USD |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | -4,950,531 | USD | 90 |
| 2024-02-14 to 2024-03-31 | -3,654,937 | USD | 47 |
| 2024-01-01 to 2024-02-13 | -897,133 | USD | 44 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 5,768,001 | USD | |
| At 2024-12-31 | 3,714,041 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 7,859,220 | USD | |
| At 2024-12-31 | 7,402,385 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 6,379,056 | USD | |
| At 2024-12-31 | 4,507,318 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 4,950,531 | USD | 90 |
| 2024-02-14 to 2024-03-31 | 3,654,937 | USD | 47 |
| 2024-01-01 to 2024-02-13 | 897,133 | USD | 44 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 2,907,827 | USD | 90 |
| 2024-02-14 to 2024-03-31 | 904,015 | USD | 47 |
| 2024-01-01 to 2024-02-13 | 764,192 | USD | 44 |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 73,345,026 | USD | |
| At 2024-12-31 | 67,142,046 | USD |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 1,271,186 | USD | |
| At 2024-12-31 | 1,464,367 | USD |
Operating lease liability
Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 1,366,585 | USD | |
| At 2024-12-31 | 1,575,499 | USD |
Gross property, plant and equipment
Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 2,554,591 | USD | |
| At 2024-12-31 | 2,554,591 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 2,102,364 | USD | |
| At 2024-12-31 | 2,026,070 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 469,659 | USD | |
| At 2024-12-31 | 1,913,175 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 564,464 | USD | |
| At 2024-12-31 | 274,749 | USD |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | -5,454,158 | USD | 90 |
| 2024-02-14 to 2024-03-31 | -1,727,483 | USD | 47 |
| 2024-01-01 to 2024-02-13 | -572,211 | USD | 44 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 2,042,704 | USD | 90 |
| 2024-02-14 to 2024-03-31 | 2,750,922 | USD | 47 |
| 2024-01-01 to 2024-02-13 | 132,941 | USD | 44 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 76,294 | USD | 90 |
| 2024-02-14 to 2024-03-31 | 76,287 | USD | 47 |
| 2024-01-01 to 2024-02-13 | 37,356 | USD | 44 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | -155,400 | USD | 90 |
| 2024-02-14 to 2024-03-31 | 1,927,454 | USD | 47 |
| 2024-01-01 to 2024-02-13 | 324,922 | USD | 44 |
Inspect the source
- Entity
- CERO THERAPEUTICS HOLDINGS, INC. / CIK 0001870404
- Captured
- 2026-09-19T11:21:59.403Z
- SEC response SHA-256
8c8c2bd97bf9d18c6c5d6af2474c4302fa2e6a98d7edbc511d62e8f44742c0ac
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001870404.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))